← Back to Search

Behavioral Intervention

HPV-PROTECT Intervention for Increasing HPV Vaccine Uptake in Young Cancer Survivors

N/A
Recruiting
Led By Wendy Landier, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
9-17y of age
Care for cancer survivors seen in the targeted clinic who are age 9-17y, ≥1y off-therapy, and reside in the state where clinic is located
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 and 24 months (all sites), and 36 months (sites d, e, f only) following implementation of the hpv-protect intervention
Awards & highlights

Study Summary

This trial will test whether an evidence-based intervention can increase HPV vaccine uptake among young cancer survivors.

Who is the study for?
This trial is for young cancer survivors aged 9-17 who are at least one year post-cancer therapy, live in the state where the clinic is located, and receive follow-up care there. Healthcare providers involved must be licensed to order vaccines and willing to complete surveys or interviews.Check my eligibility
What is being tested?
The HPV-PROTECT intervention aims to increase HPV vaccine uptake among young cancer survivors. It's an evidence-based program adapted for pediatric oncology clinics, testing whether it effectively boosts vaccination rates in this high-risk group.See study design
What are the potential side effects?
Since this trial focuses on implementing a provider-focused intervention rather than a medical product, side effects are not applicable in the traditional sense of drug-related adverse reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 9 and 17 years old.
Select...
I am a cancer survivor aged 9-17, finished treatment over a year ago, and live in the state of the clinic.
Select...
I am willing to fill out surveys or do interviews.
Select...
I am licensed to order vaccines.
Select...
I can attend follow-up appointments in person or through telehealth at the study sites.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 and 24 months (all sites), and 36 months (sites d, e, f only) following implementation of the hpv-protect intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 and 24 months (all sites), and 36 months (sites d, e, f only) following implementation of the hpv-protect intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HPV vaccine initiation rates
Secondary outcome measures
Change in provider HPV vaccine-related knowledge and practices
Provider perspectives regarding intervention feasibility, acceptability, appropriateness, fidelity
Other outcome measures
HPV vaccine series completion rates
Sustainability of HPV vaccine initiation rates

Trial Design

2Treatment groups
Experimental Treatment
Group I: Early InterventionExperimental Treatment1 Intervention
Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPV-PROTECT intervention in Year 2, and to the sustainability condition in Years 3 and 4
Group II: Delayed InterventionExperimental Treatment1 Intervention
Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned to the control condition in Years 1 and 2, to the HPV-PROTECT intervention in Year 3, and to the sustainability condition in Year 4

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,571 Previous Clinical Trials
2,264,215 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,922,199 Total Patients Enrolled
2 Trials studying Papillomavirus Vaccines
9,268 Patients Enrolled for Papillomavirus Vaccines
Wendy Landier, PhDPrincipal Investigator - University of Alabama at Birmingham
University of Alabama at Birmingham

Media Library

HPV-PROTECT (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04469569 — N/A
Papillomavirus Vaccines Research Study Groups: Delayed Intervention, Early Intervention
Papillomavirus Vaccines Clinical Trial 2023: HPV-PROTECT Highlights & Side Effects. Trial Name: NCT04469569 — N/A
HPV-PROTECT (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04469569 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

At what sites is this examination being conducted?

"University of Minnesota in Minneapolis, Baylor College of Medicine in Houston and Wake Forest University Health Sciences in Winston-Salem are three of the nine sites that compose this clinical trial."

Answered by AI

How many individuals are enrolled in this experiment?

"Affirmative. Per the clinicaltrials.gov records, this research endeavour is recruiting participants at present. It was initially shared on February 1st 2021 and has been modified as recently as May 6th 2022. 5196 patients must be enrolled within 6 different sites for completion of the study."

Answered by AI

Are there any openings for participants in this experiment?

"According to clinicaltrials.gov, this medical experiment is currently seeking test subjects. It was introduced on February 1st 2021 and saw a recent update on May 6th 2022."

Answered by AI
~1106 spots leftby Jan 2025